IDSA’s new GAS pharyngitis guidance emphasizes selective testing using clinical scoring to reduce overtreatment and antibiotic misuse.
IDSA recommends use of scoring systems to guide testing for Group A Streptococcal pharyngitis | Image Credit: © kerkezz
- © kerkezz - stock.adobe.com.
The Infectious Diseases Society of America (IDSA) has released updated clinical practice guidelines for Group A Streptococcal (GAS) pharyngitis, published October 14, 2025, marking the first major revision since 2012. The new guidance emphasizes the use of validated clinical scoring systems to guide diagnostic testing and reduce unnecessary antibiotic use (2025 IDSA Guideline).
The 2025 update highlights the continued challenge of distinguishing viral from bacterial causes of sore throat, noting that most cases are viral and self-limiting. GAS remains the cause in up to 15% of adults and 30% of children, but overdiagnosis contributes to antibiotic overuse and resistance (2025 IDSA Guideline).
For the first time, IDSA formally recommends that clinicians use clinical scoring systems—such as Centor or McIsaac criteria—to assess the likelihood of GAS before performing diagnostic testing. The goal is to identify patients with a low probability of GAS infection, in whom further testing is unlikely to change management.
“The principal utility of a scoring system is to identify patients with low probability of GAS pharyngitis,” the panel stated, adding that doing so may reduce false positives, unnecessary testing, and antibiotic prescribing (2025 IDSA Guideline).
The guideline issues a conditional recommendation with very low certainty of evidence, reflecting the limited number of comparative studies, but notes that the balance of benefits and harms supports implementation.
The 2012 IDSA guideline emphasized throat swab testing—via rapid antigen detection test (RADT) and culture—as the diagnostic standard, given that clinical features alone could not reliably differentiate bacterial from viral causes (2012 IDSA Guideline).1,2
In contrast, the 2025 update recommends incorporating a pretest scoring system to guide who should be tested, representing a shift toward more selective and evidence-based testing.
Unchanged in the new guidance is that children under 3 years old remain excluded from testing recommendations due to atypical presentation and low incidence.
While the 2012 guideline focused heavily on antibiotic regimens, including penicillin or amoxicillin as first-line therapy, the 2025 update defers treatment discussions to future installments, with this first part focusing solely on diagnosis and testing strategy.
A systematic review identified six observational studies comparing scoring systems with clinician judgment alone (2025 IDSA Guideline). Studies using Centor, McIsaac, and Breese criteria showed similar or slightly higher diagnostic accuracy compared to usual clinical practice.
The IDSA panel concluded that:
The new recommendation applies to both adults and children but not to those under 3 years old or with atypical clinical presentations. The guideline also advises clinicians to consider high-risk individuals for testing regardless of score—such as patients with household GAS exposure, previous rheumatic fever, or symptoms suggesting systemic infection.
The IDSA notes that future updates will address testing modalities, treatment options, and post-treatment management (2025 IDSA Guideline).
References:
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
